Penumbra, Inc. $PEN Shares Bought by Capital World Investors

Capital World Investors lifted its stake in Penumbra, Inc. (NYSE:PEN) by 2.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 426,456 shares of the company’s stock after acquiring an additional 10,724 shares during the period. Capital World Investors’ holdings in Penumbra were worth $132,589,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently made changes to their positions in the company. Larson Financial Group LLC lifted its stake in shares of Penumbra by 4,100.0% in the 4th quarter. Larson Financial Group LLC now owns 84 shares of the company’s stock worth $26,000 after acquiring an additional 82 shares during the period. Morse Asset Management Inc acquired a new stake in shares of Penumbra in the 4th quarter worth approximately $39,000. Rothschild Investment LLC acquired a new stake in shares of Penumbra in the 3rd quarter worth approximately $40,000. Farther Finance Advisors LLC lifted its stake in shares of Penumbra by 27.1% in the 4th quarter. Farther Finance Advisors LLC now owns 178 shares of the company’s stock worth $55,000 after acquiring an additional 38 shares during the period. Finally, Allworth Financial LP lifted its stake in shares of Penumbra by 36.2% in the 3rd quarter. Allworth Financial LP now owns 241 shares of the company’s stock worth $61,000 after acquiring an additional 64 shares during the period. 88.88% of the stock is owned by institutional investors and hedge funds.

Penumbra Stock Down 0.1%

PEN stock opened at $320.28 on Tuesday. Penumbra, Inc. has a 12 month low of $221.26 and a 12 month high of $362.41. The firm has a market cap of $12.60 billion, a PE ratio of 73.80, a P/E/G ratio of 1.96 and a beta of 0.71. The firm has a 50 day simple moving average of $326.54 and a 200 day simple moving average of $326.64. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.02 and a quick ratio of 3.95.

Penumbra (NYSE:PEN) last released its earnings results on Wednesday, May 6th. The company reported $0.82 EPS for the quarter, missing the consensus estimate of $1.06 by ($0.24). Penumbra had a net margin of 11.76% and a return on equity of 10.87%. The business had revenue of $374.76 million for the quarter, compared to analyst estimates of $370.47 million. During the same period in the prior year, the company earned $0.83 earnings per share. The firm’s revenue for the quarter was up 15.6% on a year-over-year basis. Equities research analysts forecast that Penumbra, Inc. will post 5.08 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on PEN shares. UBS Group reaffirmed a “neutral” rating and issued a $374.00 price target on shares of Penumbra in a research note on Thursday, February 26th. Wall Street Zen raised shares of Penumbra to a “hold” rating in a research note on Saturday, May 9th. Evercore reissued an “outperform” rating and set a $335.00 target price on shares of Penumbra in a research note on Thursday, May 7th. Finally, Citigroup cut their target price on shares of Penumbra from $374.00 to $350.00 and set a “neutral” rating for the company in a research note on Thursday, May 7th. Three equities research analysts have rated the stock with a Buy rating and fourteen have issued a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $361.33.

Insider Activity at Penumbra

In related news, Director Harpreet Grewal sold 100 shares of the company’s stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $328.22, for a total value of $32,822.00. Following the completion of the sale, the director owned 8,719 shares in the company, valued at approximately $2,861,750.18. This represents a 1.13% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 2.90% of the company’s stock.

Penumbra Company Profile

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.